col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Elsevier: European Journal of Pharmacology
  original article Date Title Authors   All Authors
1 [GO] 2021―Jul―22 SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Shirin Hafezi, Rasha Assiri, Saleh Al-Muhsen, et al. (+2)
2 [GO] 2021―Jul―07 Effects of antiviral drug therapy on dynamic thiol/disulphide homeostasis and nitric oxide levels in COVID-19 patients Ayşe Özlem Mete, Kübra Koçak, Ahmet Saracaloglu, Seniz Demiryürek, Özgür Altınbaş, Abdullah T. Demiryürek
3 [GO] 2021―Jun―12 Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies Kiarash Saleki, Shakila Yaribash, Mohammad Banazadeh, Ehsan Hajihosseinlou, Mahdi Gouravani, Amene Saghazadeh, Nima Rezaei
4 [GO] 2021―Jun―07 Efficacy and safety of Dihydroorotate dehydrogenase (DHODH) inhibitors “Leflunomide” and “Teriflunomide” in Covid-19: A narrative review. Hardeep Kaur, Phulen Sarma, Anusuya Bhattacharyya, Saurabh Sharma, Neeraj Chhimpa, Manisha Prajapat, et al. (+7)
5 [GO] 2021―May―17 Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment Abdolkarim Hosseini, Hadi Esmaeili Gouvarchin Ghaleh, Hossein Aghamollaei, Mahdi Fasihi Ramandi, Gholamhossein Alishiri, Alireza Shahriary, et al. (+3)
6 [GO] 2021―May―17 Azithromycin: Immunomodulatory and Antiviral Properties for SARS-CoV-2 Infection Mohammad Rafi Khezri, Naime Majidi Zolbanin, Morteza Ghasemnejad-berenji, Reza Jafari
7 [GO] 2021―May―15 Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Yaaser Q. Almulaiky, Natália Cruz-Martins, Gaber El-Saber Batiha
8 [GO] 2021―Apr―03 Virtual high throughput screening: Potential Inhibitors for SARS-CoV-2 PLPRO and 3CLPRO Proteases Dhananjay Jade, Selvaraj Ayyamperumal, Vyshnavi Tallapaneni, Chandrasekar Moola Joghee Nanjan, Sagar Barge, Surender Mohan, Moola Joghee Nanjan
9 [GO] 2021―Mar―13 COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not Morry Silberstein
10 [GO] 2021―Mar―02 Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19 Bertram Pitt, Nadia R. Sutton, Zhong Wang, Sascha N. Goonewardena, Michael Holinstat
11 [GO] 2021―Feb―25 Brief review on repurposed drugs and vaccines for possible treatment of COVID-19 Priyasha De, Ishita Chakraborty, Bhargavi Karna, Nirmal Mazumder
12 [GO] 2021―Feb―17 No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial Hamidreza Jamaati, Seyed MohammadReza Hashemian, Behrooz Farzanegan, Majid Malekmohammad, Payam Tabarsi, Majid Marjani, et al. (+12)
13 [GO] 2021―Feb―04 Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis Afra Rezagholizadeh, Sajad Khiali, Parvin Sarbakhsh, Taher Entezari-Maleki
14 [GO] 2021―Feb―03 Chloroquine: autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? Pawan Sharma, Kielan D. McAlinden, Saeid Ghavami, Deepak A. Deshpande
15 [GO] 2021―Feb―03 COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes Mohammad A.I. Al-Hatamleh, Ma’mon M. Hatmal, Walhan Alshaer, Engku Nur Syafirah E.A. Rahman, Manali Haniti Mohd-Zahid, Dina M. Alhaj-Qasem, et al. (+8)
16 [GO] 2021―Feb―02 SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study Krishnaprasad Baby, Swastika Maity, Chetan H. Mehta, Akhil Suresh, Usha Y. Nayak, Yogendra Nayak
17 [GO] 2021―Jan―27 Association of ACE inhibitors and Angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study R.A.H.U.L. Parit, S.R.I.D.H.A.R. Jayavel
18 [GO] 2021―Jan―23 Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2 Shuai Ge, Xiangjun Wang, Yajing Hou, Yuexin Lv, Cheng Wang, Huaizhen He
19 [GO] 2021―Jan―20 A review of potential suggested drugs for coronavirus disease (COVID-19) treatment Parastoo Tarighi, Samane Eftekhari, Milad Chizari, Mahsa Sabernavaei, Davod Jafari, Parastoo Mirzabeigi
20 [GO] 2021―Jan―10 Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic Sobia Noreen, Irsah Maqbool, Asadullah Madni
21 [GO] 2020―Dec―31 Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations Aditya K. Padhi, Aniruddha Seal, Javed Masood Khan, Maqusood Ahamed, Timir Tripathi
22 [GO] 2020―Dec―18 Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel Zheng Zequn, W.U. Yujia, Q.I.A.N. Dingding, L.I.A.N. Jiangfang
23 [GO] 2020―Dec―01 Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): in silico analysis Bilal Çakır, Betül Okuyan, Göksel Şener, Tuğba Tunalı-Akbay
24 [GO] 2020―Dec―01 Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach Abida Batool, Nousheen Bibi, Farhat Amin, Mohammad Amjad Kamal
25 [GO] 2020―Nov―27 Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2) Chaima Mouffouk, Soumia Mouffouk, Sara Mouffouk, Leila Hambaba, Hamada Haba
26 [GO] 2020―Nov―25 COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies Kajal Rawat, Puja Kumari, Lekha Saha
27 [GO] 2020―Nov―20 A Comprehensive Review on Potential Therapeutics Interventions for COVID-19 Heerak Chugh, Amardeep Awasthi, Yashi Agarwal, Rajesh K. Gaur, Gagan Dhawan, Ramesh Chandra
28 [GO] 2020―Nov―20 A Review on Possible Mechanistic Insights of Nitazoxanide for Repurposing in COVID-19 Amit S. Lokhande, Padma V. Devarajan
29 [GO] 2020―Nov―20 An overview of viruses discovered over the last decades and drug development for the current Pandemic Agha Zeeshan Mirza, Hina Shamshad, Faisal Abdulrhman Osra, Turki M. Habeebullah, Moataz Morad
30 [GO] 2020―Nov―06 Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19 Himanshu G. Toor, Devjani I. Banerjee, Soumya Lipsa Rath, Siddhi A. Darji
31 [GO] 2020―Nov―03 Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead Harmanjit Singh, Prerna Chauhan, Ashish Kumar Kakkar
32 [GO] 2020―Nov―01 Functional and druggability analysis of the SARS-CoV-2 proteome Claudio N. Cavasotto, Maximiliano Sánchez Lamas, Julián Maggini
33 [GO] 2020―Oct―31 COVID-19 and antimalarials. Have we been doing it wrong all along? Cismaru Cosmin Andrei, Cismaru Gabriel Laurentiu, Nabavi Seyed Fazel, Nabavi Seyed Mohammad, Berindan-Neagoe Ioana
34 [GO] 2020―Oct―29 Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies Pooja M, Gangavaram Jyothi Reddy, Kanipakam Hema, Sujatha Dodoala, Bharathi Koganti
35 [GO] 2020―Oct―29 In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain Nouredine Behloul, Sarra Baha, Yuqian Guo, Zhifang Yang, Ruihua Shi, Jihong Meng
36 [GO] 2020―Oct―29 Science unites a troubled world: Lessons from the pandemic George W. Booz, Fouad A. Zouein
37 [GO] 2020―Oct―24 Recent progress of antiviral therapy for coronavirus disease 2019 Mengmeng Zhao, Jishou Zhang, Hanli Li, Zhen Luo, Jing Ye, Yao Xu, et al. (+6)
38 [GO] 2020―Oct―24 Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 Mpro using molecular docking and dynamics simulations studies Shahzaib Ahamad, Hema Kanipakam, Shweta Birla, Md Shaukat Ali, Dinesh Gupta
39 [GO] 2020―Oct―22 Gordian Knot: Gastrointestinal lesions caused by three highly pathogenic coronaviruses from SARS-CoV and MERS-CoV to SARS-CoV-2 Xiang Meng, Qiu-yue Lou, Wen-ying Yang, Ran Chen, Wen-hua Xu, Yang Yang, et al. (+3)
40 [GO] 2020―Oct―21 Translating bioactive peptides for COVID-19 therapy Khushwant S. Bhullar, Steven J. Drews, Jianping Wu
41 [GO] 2020―Oct―18 Renin angiotensin system at the interface of COVID-19 infection Rukhsana Gul, Kim Uh-Hyun, Assim A. Alfadda
42 [GO] 2020―Oct―13 Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic Ranjana Bhandari, Garima Khanna, Anurag Kuhad
43 [GO] 2020―Oct―13 Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2 Shaik Mahammad Nayeem, Ershad Mohammed Sohail, Gajjela Priyanka Sudhir, Munnangi Srinivasa Reddy
44 [GO] 2020―Oct―11 Treatment for COVID-19: An overview Cristina Stasi, Silvia Fallani, Fabio Voller, Caterina Silvestri
45 [GO] 2020―Oct―07 Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review Akram Yarmohammadi, Mostafa Yarmohammadi, Sajad Fakhri, Haroon Khan
46 [GO] 2020―Oct―06 Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment Yan Wang, Lei Chen
47 [GO] 2020―Oct―04 Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19? Luis H.A. Costa, Bruna M. Santos, Luiz G.S. Branco
48 [GO] 2020―Oct―01 New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19 Manar Mohammed El Tabaa, Maram Mohammed El Tabaa
49 [GO] 2020―Sep―22 Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19 Tania Islam, Md Rezanur Rahman, Busra Aydin, Hande Beklen, Kazim Yalcin Arga, Md Shahjaman
50 [GO] 2020―Sep―19 A review of medications used to control and improve the signs and symptoms of COVID-19 patients Kiavash Hushmandi, Saied Bokaie, Mehrdad Hashemi, Ebrahim Rahmani Moghadam, Mehdi Raei, Farid Hashemi, et al. (+3)
51 [GO] 2020―Sep―15 Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients Rui Huang, Chuanwu Zhu, Leyang Xue, Chunyang Li, Xiaomin Yan, Songping Huang, et al. (+18)
52 [GO] 2020―Sep―15 Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic Faezeh Monji, Abrar Al-Mahmood Siddiquee, Farshad Hashemian
53 [GO] 2020―Sep―12 Possibility of magnesium supplementation for supportive treatment in patients with COVID-19 Chuan-Feng Tang, Hong Ding, Rui-Qing Jiao, Xing-Xin Wu, Ling-Dong Kong
54 [GO] 2020―Sep―12 COVID-19 associated complications and potential therapeutic targets. Jasmin D. Monpara, Srushti J. Sodha, Pardeep K. Gupta
55 [GO] 2020―Sep―12 Curcumin, a traditional spice component, can hold the promise against COVID-19? Vivek Kumar Soni, Arundhati Mehta, Yashwant Kumar Ratre, Atul Kumar Tiwari, Ajay Amit, Rajat Pratap Singh, et al. (+4)
56 [GO] 2020―Sep―11 Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 Upinder Kaur, Kumudini Acharya, Ritwick Mondal, Amit Singh, Luciano Saso, Sasanka Chakrabarti, Sankha Shubhra Chakrabarti
57 [GO] 2020―Sep―11 Macrophage responses associated with COVID-19: A pharmacological perspective George W. Booz, Raffaele Altara, Ali H. Eid, Zena Wehbe, Souha Fares, Hassan Zaraket, et al. (+2)
58 [GO] 2020―Sep―01 The prophylaxis and treatment potential of supplements for COVID-19 Adeleh Sahebnasagh, Fatemeh Saghafi, Razieh Avan, Amirhosein Khoshi, Masoud Khataminia, Mohammadreza Safdari, et al. (+3)
59 [GO] 2020―Aug―22 Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. Nousheen Bibi, Sana Gul, Johar Ali, Mohammad Amjad Kamal
60 [GO] 2020―Aug―22 Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2 Ashkan Madadlou
61 [GO] 2020―Aug―20 Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial Daryoush Hamidi Alamdari, Ahmad Bagheri Moghaddam, Shahram Amini, Mohammad Reza Keramati, Azam Moradi Zarmehri, Aida Hamidi Alamdari, et al. (+4)
62 [GO] 2020―Aug―15 The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis Parham Habibzadeh, Mohammad Mofatteh, Saeid Ghavami, Jamshid Roozbeh
63 [GO] 2020―Aug―08 What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results Vanessa Aparecida Marcolino, Tatiana Colombo Pimentel, Carlos Eduardo Barão
64 [GO] 2020―Aug―06 COVID-19: A review of the proposed pharmacological treatments Sarah Lam, Andrew Lombardi, Aviv Ouanounou
65 [GO] 2020―Aug―06 In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2 Balaji Gowrivel Vijayakumar, Deepthi Ramesh, Annu Joji, Jayadharini Jayachandra prakasan, Tharanikkarasu Kannan
66 [GO] 2020―Aug―05 Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective Suliman Khan, Huseyin Tombuloglu, Sameh E. Hassanein, Surya Rehman, Ayhan Bozkurt, Emre Cevik, et al. (+4)
67 [GO] 2020―Aug―04 Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations Alireza Paniri, Mohammad Mahdi Hosseini, Ahmad Rasoulinejad, Haleh Akhavan-Niaki
68 [GO] 2020―Aug―03 In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2 Rujuta R. Deshpande, Arpita Pandey Tiwari, Narendra Nyayanit, Manisha Modak
69 [GO] 2020―Aug―01 An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment Alexander V. Lopachev, Rogneda B. Kazanskaya, Anastasiya V. Khutorova, Tatiana N. Fedorova
70 [GO] 2020―Jul―31 Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection Gayathri Krishna, Vinod Soman Pillai, Mohanan Valiya Veettil
71 [GO] 2020―Jul―31 Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting Sourena Sharifkashani, Melika Arab Bafrani, Alireza Soltani Khaboushan, Marzieh Pirzadeh, Ali Kheirandish, Hanie Yavarpour_Bali, et al. (+3)
72 [GO] 2020―Jul―25 OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath Ankit Awasthi, Sukriti Vishwas, Leander Corrie, Rajesh Kumar, Rubiya Khursheed, Jaskiran Kaur, et al. (+11)
73 [GO] 2020―Jul―17 Virology, pathogenesis, diagnosis and in-line treatment of COVID-19 Pavan Kumar Samudrala, Pramod Kumar, Kamlesh Choudhary, Nagender Thakur, Gaurav Suresh Wadekar, Richa Dayaramani, et al. (+2)
74 [GO] 2020―Jul―17 Advances in the possible treatment of COVID-19: A review. Pankaj Chibber, Syed Assim Haq, Irfan Ahmed, Nusrit Iqbal Andrabi, Gurdarshan Singh
75 [GO] 2020―Jul―15 Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know? Antonio Vitiello, Francesco Ferrara
76 [GO] 2020―Jul―04 Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus Calvin A. Omolo, Nikki Soni, Victoria Oluwaseun Fasiku, Irene Mackraj, Thirumala Govender
77 [GO] 2020―Jun―30 Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19 Mohamed A. El-Missiry, Ziad M.A. El-Missiry, Azza I. Othman
78 [GO] 2020―Jun―27 Drug treatment of coronavirus disease 2019 (COVID-19) in China. Zhe Jin, Jing-Yi Liu, Rang Feng, Lu Ji, Zi-Li Jin, Hai-Bo Li
79 [GO] 2020―Jun―27 Current pharmacological treatments for SARS-COV-2: A narrative review Giulio Nittari, Graziano Pallotta, Francesco Amenta, Seyed Khosrow Tayebati
80 [GO] 2020―Jun―17 Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? Antoni Sureda, Javad Alizadeh, Seyed Fazel Nabavi, Ioana Berindan Neagoe, Cosmin Andrei Cismaru, Philippe Jeandet, et al. (+4)


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.010 sec